மயக்க மருந்து & மருத்துவ ஆராய்ச்சி
திறந்த அணுகல்

சுருக்கம்

Platelet Aggregometry May Not Identify Clopidogrel-Treated Patients at High Risk of Peri-Operative Bleeding in Dialysis Access Surgery: A Pilot Study

Benjamin S Martinez, Irina Gasanova, Adebola O Adesanya, Ingemar Davidson and Ravindra Sarode

Patients treated with Clopidogrel are usually instructed to discontinue treatment for 7 days prior to surgery because of concern for excessive peri-operative blood loss. Limited data exist regarding blood loss resulting from continuing treatment with Clopidogrel. Our goal was to compare peri-operative blood loss in Clopidogrel (CC) treated patients with Non-Clopidogrel (NC) patients undergoing upper extremity dialysis access surgery. Methods: Following informed consent, 23 patients, 18-90 years old were enrolled in a pilot, prospective study. Nine patients continued treatment with Clopidogrel, while 14 patients had no exposure to the drug. Vascular fistula or graft placement was accomplished under brachial plexus anesthesia and sedation. ADP (adenosine diphosphate) induced inhibition of platelets was assayed by Impedance-based Whole Blood Platelet Aggregation (IWBPA) on immediate preoperative blood sample obtained from all participants to determine baseline platelet aggregation status (Figure 1). Intra-operative blood loss (IBL) was estimated from suction canister output and sponge weights. Interventions such as blood or blood product transfusion were noted. Postoperative bruising or bleeding for up to 24 hours was recorded.